Our recent study in patients with EGFR-mutant advanced NSCLC receiving Osimertinib showed that, compared to salvage radiotherapy in patients with oligo-progressive disease, consolidative radiotherapy targeting EGFR-TKI resistant clones at all oligo-residual tumor sites potentially offered a survival advantage [10]. Here, EGFR is linked to neoplasm.